IMC£¨Imaging Mass Cytometry£©¿Õ¼äµ°°×ÖÊ×éѧ¼¼ÊõÊÇÔÚCyTOF£¨Mass Cytometry£©µ¥Ï¸°ûÖÊÆ×Á÷ʽ¼¼ÊõµÄ»ù´¡ÉÏ£¬À©Õ¹ºÍÑÓÉì³öÀ´µÄ³ÉÏñÖÊÆ×Á÷ʽ¼¼Êõ¡£ÓëCyTOFÏà±È£¬IMCÔö¼ÓÁËHyperion ×éÖ¯ÖÊÆ׳ÉÏñ×é¼þ£¬¿ÉÒÔ¶Ô×éÖ¯ÇÐƬ£¬ÓÈÆäÊÇʯÀ¯×éÖ¯½øÐе°°×ÖÊ×éÖ¯ÔλµÄ¶¨ÐÔ¶¨Á¿¼ì²â¡£IMCͬÑù²ÉÓÿ¹Ìå½áºÏÏ¡ÍÁ½ðÊô±êÇ©µÄÐÎʽ±ê¼ÇÌض¨Ï¸°ûµ°°×£¬Í¨¹ýICP-MS½øÐнðÊô±êǩʶ±ðºÍ¼ì²â£¬»ñÈ¡µ°°×Öʼ°ÆäÌض¨Ï¸°ûÔÚ×éÖ¯½á¹¹Öеķá¶ÈÊý¾Ý¡£Ä¿Ç°£¬k8¿·¢(Öйú)µÄIMC¼¼Êõƽ̨ÒѾ¶Ô47ÖÖÖØÒªµ°°×±êÇ©¿¹Ìå½øÐÐÁËÑéÖ¤£¬¿ÉʵÏÖ¶ÔÕâЩµ°°×ÖʵÄ׼ȷ¼ì²â¡£Í¬Ê±£¬Èç¹ûÏÖÓп¹Ìå²»ÄÜÂú×ãÑо¿ÐèÇó£¬k8¿·¢(Öйú)»¹¿ÉÌṩÌض¨¿¹ÌåµÄ¶¨ÖÆ¿ª·¢·þÎñ¡£
| ¼¼ÊõÔÀí
IMCÔÚ2014ÄêÓÉGiesen CµÈÈËÔÚNat Methods·¢±íµÄÑо¿ÖÐÊ״α»Ó¦Óá£ËûÃǽ«ÐÂÐͼ¤¹âÏûÈÚ×°ÖÃÒýÈëµ½ÖÊÆ×ÒǼì²âÖС£¹Ì¶¨ÔÚÔز£Æ¬ÉϵÄ×éÖ¯ÇÐƬ»òϸ°ûÓÃÒ»×éÏ¡ÍÁ½ðÊô±êǩżÁªµÄ¿¹Ìå½øÐбê¼Çºó±»²åÈëÏûÈÚÊÒÖУ¬ÔÚÏûÈÚÊÒÖÐͨ¹ýÔÚ213nmϲÙ×÷µÄÂö³å¼¤¹âɨÃè×éÖ¯²¢¾Û½¹µ½1μmÖ±¾¶µÄ¹â°ß´óС¡£À´×ÔÏûÈÚµãµÄ×éÖ¯ÔÚÿ´Î¼¤¹âÕÕÉäʱ±»Æø»¯£¬²¢ÓɾßÓиßʱ¼ä±£Õæ¶ÈµÄ¶èÐÔÆøÌåÁ÷Я´øµ½µç¸ÐñîºÏµÈÀë×ÓÌåÀë×ÓÔ´ÖУ¬Ö®ºóͨ¹ý(CyTOF®) µÄÖÊÁ¿¼ì²âÆ÷½øÐÐͬ²½·ÖÎö¡£Óëÿ¸öµãÏà¹ØµÄ½ðÊô±êÇ©±»Í¬Ê±²âÁ¿£¬ÔÙ¸ù¾Ýÿ¸öµãµÄ×ø±êλÖýøÐÐË÷Òý¡£Ôز£Æ¬ÑØ×ÅɨÃèÏßÔڹ̶¨µÄ¼¤¹âÊøÏ·½ÖðµãÒƶ¯É¨Ã裬˳ÐòɨÃèºó×îÖÕ²úÉú±é¼°×éÖ¯»ò¸ÐÐËȤÇøÓòµÄËùÓае°°×µÄÐźÅÇ¿¶Èͼ¡£¾¹ýÈí¼þ´¦ÀíºÍ½µÎ¬·ÖÎö£¬»ñµÃ¾ßÓÐ×éÖ¯½á¹¹µÄµ°°×·Ö²¼Í¼Æ׺Íϸ°ûÑÇȺ·Ö²¼Í¼Æס£
£¨Òý×Ô Chang et al. 2017£©
| ¼ì²âÁ÷³Ì
1. ʹÓÃÓ벻ͬϡÍÁ½ðÊôżÁªµÄ¶àÖÖ¿¹Ìå¶Ô×éÖ¯ÇÐƬ»ò¹Ì¶¨»¯Ï¸°û½øÐÐͬ²½±ê¼Ç;
2. ÔÚ Hyperion×éÖ¯ÖÊÆ׳ÉÏñ×é¼þÖÐͨ¹ýÂö³å¼¤¹â½øÐÐ×éÖ¯ÏûÈÚ;
3. Æø»¯µÄÑùƷͨ¹ý¶èÐÔÆøÌåµÄµÈÀë×ÓÌåÁ÷±»Çý¶¯µ½CyTOFÖÊÆ×ÒǵÄÖÊÁ¿¼ì²âÆ÷½øÐзÖÎö£¬Öؽ¨×éÖ¯ÒÔ¼°Óëÿ¸ö¼ì²âµã·á¶ÈµÄ¹ØÁªÐÔ£»
4. ͨ¹ý²»Í¬µÄÈí¼þ½øÐÐÐźţ¨Í¼Ïñ£©·ÖÎöºÍÖصþ¡£
£¨Òý×Ô Cereceda et al. 2021£©
| IMC¼¼ÊõÓÅÊÆ
¡ñ IMCÓµÓÐCyTOF¼¼ÊõÏà±ÈÓÚÆäËû¼¼ÊõµÄËùÓÐÓÅÊÆ¡£ÀýÈ磺IMC¼¼ÊõÓÉÓÚ¼ì²âµÄÊǵ°°×ÖʵÄMarker£¬Æäϸ°û·ÖÐÍÊý¾ÝÏà½ÏÓÚµ¥Ï¸°û²âÐò¸üΪ׼ȷ£¬¶ÔÓÚÓëÕ¼±È½ÏСµÄϸ°ûÑÇȺҲÄܹ»¾«È··ÖÎö¡£
¡ñ ÖؽðÊô±êÇ©·Ç³£Îȶ¨£¬Í¬Åú±ê¼ÇµÄ¿¹Ì壬ÔÚ 2 ÖÜÄÚ¼ì²âÐźÅÒÀÈ»Îȶ¨¡£²»»á³öÏÖ¼ì²âͨµÀÖ®¼ä´ÜÉ«ºÍÏ໥¸ÉÈŵÄÇé¿ö¡£
¡ñ IMC¿ÉÔÚϸ°ûºÍ×é֯ˮƽÉÏͬʱ¼ì²â¶à´ï 47 ÖÖµ°°×ÖÊ£¬ÆäͨÁ¿Ô¶Ô¶¸ßÓÚ³£¹æµÄÃâÒß×éÖ¯¶àÖØȾɫ¼¼Êõ£¬¿ÉÒÔ»ñµÃ¸ü¼Ó·á¸»µÄµ°°×Öʼì²âÊý¾Ý¡£
¡ñ IMC¼¼ÊõʵÏÖÁ˿ռ䵰°×ÖÊ×éºÍ¿Õ¼äϸ°û×é³ÉµÄ¶¨ÐÔ¶¨Á¿·ÖÎö£¬¶ÔÓÚÀí½â¼²²¡·¢Éú»úÀíºÍ²»Í¬¼²²¡×´Ì¬×îÕæʵµÄ²¡ÒòÌṩÁËÖ±½ÓÖ¤¾Ý¡£²¢ÇÒ£¬ÕâЩÔÚ×éÖ¯Öбí´ïµÄÌض¨µ°°×Öʺ;ۼ¯µÄϸ°ûÑÇȺ£¬Ò²Îª½øÒ»²½µÄÁÙ´²ÓÃÒ©Æðµ½Á˹ؼüµÄÖ¸µ¼×÷Óá£
| IMC¼ì²âÁбí
Ä¿Ç°£¬k8¿·¢(Öйú)µÄIMC¼¼Êõƽ̨ÒѾ¶Ô47ÖÖÖØÒªµ°°×±êÇ©¿¹Ìå½øÐÐÁËÑéÖ¤£¬¿ÉʵÏÖ¶ÔÕâЩµ°°×ÖʵÄ׼ȷ¼ì²â¡£Í¬Ê±£¬Èç¹ûÏÖÓп¹Ìå²»ÄÜÂú×ãÑо¿ÐèÇó£¬k8¿·¢(Öйú)»¹¿ÉÌṩÌض¨¿¹ÌåµÄ¶¨ÖÆ¿ª·¢·þÎñ¡£
¼ì²âÁбí
| IMCÓ¦Ó÷½Ïò
¡ñ Ñ°ÕÒÓë¼²²¡·¢Éú¡¢·¢Õ¹¡¢¸´·¢Ïà¹ØµÄÉúÎï±êÖ¾ÎÔçÆÚÕï¶Ï¡¢°éËæÕï¶Ï¡¢¸´·¢Ô¤²â¡¢¼²²¡·ÖÐ͵ȣ©
¡ñ Ìض¨ÈËȺ¡¢Ìض¨²¿Î»µÄÃâÒßÌØÕ÷·ÖÎö£¨ÈçÔи¾¡¢Ì¥¶ù¡¢³¦µÀµÈ£©
¡ñ ÐÂÒ©Ò©°ÐµÄ·¢ÏÖÓëÑéÖ¤£¨Ïȵ¼»¯ºÏÎï¡¢¼¤Ã¸ÒÖÖƼÁ¡¢µ¥¿¹Ò©ÎïµÈ£©
¡ñ µ¥Ï¸°û²âÐòÊý¾ÝµÄÑéÖ¤ÓëÉîÈëϸ°û·ÖÐÍ
| Ñù±¾ÒªÇó
¡ñ ÇÐƬÑù±¾ÐèÒªÓÃʯÀ¯ÓÍÃÜ·âºó4¶È±£´æ£»À¯¿éÑù±¾4¶È±£´æ
¡ñ Á¬ÐøÇÐƬ£¨Serial sections£©£¬±ãÓÚËø¶¨Ä¿±êÇøÓò
¡ñ ºñ¶ÈСÓÚµÈÓÚ7μm
¡ñ ×éÖ¯FFPEÑù±¾¾¡Á¿ÐÂÏÊ£¬×îºÃÊÇ°ëÄêÒÔÄÚÖÆ×÷£¬ÒÔʯÀ¯¿éΪ¼Ñ¡£
| Ó¦Óð¸Àý
°¸ÀýÒ» IMC·¢ÏÖÁËÓ×ÄêÐÍƤ¼¡Ñ׺ͺì°ßÀÇ´¯×éÖ¯Öв»Í¬µÄ¿Õ¼äϸ°ûÑÇÐÍ
Ñо¿Õ߶Ô6ÀýÓ×ÄêÐÍƤ¼¡Ñ×£¨JDM£©ºÍ4Àýºì°ßÀÇ´¯»¼Õߣ¨cSLE£©µÄƤ·ô×éÖ¯½øÐÐÁËIMC·ÖÎö£¬×ܹ²¼ì²âÁË°üº¬CD14, CD15, CD16, CD56, CD68, CD11c, HLA-DR, BDCA2, CD20, CD27, CD138, CD4, CD8, E-cadherin, CD31, pan-keratin ºÍ collagen type IµÄ17¸öµ°°×¡£½á¹ûÔÚJDMºÍcSLEƤ·ôÖмø¶¨ÁË14¸öϸ°ûȺ£¬°üÀ¨CD14+ºÍCD68+¾ÞÊÉϸ°û¡¢¹ÇËèºÍ½¬Ï¸°ûÑùÊ÷ͻ״ϸ°û (pDC)¡¢CD4+ºÍCD8+ Tϸ°ûºÍBϸ°û¡£×ÜÌå¶øÑÔ£¬cSLEƤ·ôÓнϸߵÄÑ×֢ϸ°û½þÈó£¬CD14+¾ÞÊÉϸ°û¡¢pDCºÍ CD8+ Tϸ°ûÒÔ¼°ÃâÒß-ÃâÒßϸ°û»¥×÷ÏÔÖøÔö¼Ó¡£¶øJDMƤ·ô±íÏÖ³ö¸üÇ¿µÄÏÈÌìÃâÒßÌØÕ÷£¬¾ßÓиü¸ßµÄCD14+¾ÞÊÉϸ°ûÕ¼±ÈºÍÏÔÖøÔö¼ÓµÄÄÚƤ-ÃâÒßϸ°û¼äµÄ¿Õ¼ä»¥×÷¹Øϵ¡£
°¸Àý¶þ IMC½ÒʾÏÈÐIJ¡×éÖ¯µÄÃâÒß΢»·¾³ÌØÕ÷
2022Äê·¢±íÔÚNatureÉϵÄÒ»ÏîÑо¿Í¨¹ýIMC¼¼Êõ·ÖÎöÁËÏÈÐIJ¡£¨CHD£©»¼ÕßÐÄÔà×éÖ¯ÃâÒß΢»·¾³µÄ״̬ºÍÌØÕ÷¡£Ñо¿Õß¼ì²âÁË21¸ö»¼ÕߺÍÕý³£¾èÏ×ÕßÐÄÔà×éÖ¯ÇÐƬµÄ23¸öÑ×Ö¢µ°°×¡£³É´Ø·ÖÎö¼ø±ðÁË11¸öѪ¹ÜÖÜϸ°û´Ø£¬ÕâЩϸ°û´Ø°üº¬ÁËѪ¹Üƽ»¬¼¡Ï¸°û¡¢¾ÞÊÉϸ°û¡¢³ÉÏËάϸ°ûºÍÄÚƤϸ°ûµÈ¡£ÌرðÊǼø¶¨ÁË3¸ö·Ö±ð±í´ïCD68, CD14 and CD163µÄ¾ÞÊÉϸ°û£¨MΦ1–MΦ3£©¡£ÆäÖÐMΦ1ºÍMΦ2µÄ¶¨Î»ÁÚ½üÓëÄÇЩ±í´ïÃâÒßÒÖÖÆÒò×Ó£¨PD-L1¡¢CD73¡¢CD33£©µÄTϸ°û£¬ËµÃ÷ÁËÕâЩ¾ÞÊÉϸ°ûºÍÒÖÖÆÐÔTϸ°û¼ä´æÔڷdz£ÖØÒªµÄ¹ØÁª¡£½áºÏÐÄÔà×éÖ¯µÄµ¥Ï¸°û²âÐò½á¹û£¬·¢ÏÖÁËMΦ2ϸ°û¸ß±í´ïIFNγÐźŻùÒò£¬¶øIFNγ¿ÉÒÔͨ¹ýÓÕµ¼PD-L1µÄ±í´ïÒÖÖÆTϸ°û»îÐÔ£¬Òò´ËIMC¶Ôµ¥Ï¸°û²âÐòÌṩÁË×éÖ¯¿Õ¼äˮƽÉϵÄÑéÖ¤¡£×îºóÑо¿Õß·¢ÏÖÁ˶¨Î»ÔÚACTA2+ Ѫ¹Ü¸½½üµÄ±í´ï¿¹Ñ×Ö¢µ°°×µÄTϸ°ûÊýÄ¿ÔÚ»¼ÕßÖÐÏÔÖø¸ßÓÚÕý³£¾èÏ×Õߣ¬ËµÃ÷ÁËÏÈÐIJ¡»¼ÕßµÄÐÄÔà×éÖ¯´¦ÓÚÃâÒßÒÖÖÆ״̬¡£
| Ïà¹ØÎÄÏ×£º
[1]. Cereceda K, Jorquera R, Villarroel-Espíndola F. Advances in mass cytometry and its applicability to digital pathology in clinical-translational cancer research. Adv Lab Med 2022;3(1): 5–16.£¨°¢Í¼ÂÞ·ÂåÅå×È·ÅåÀ×˹»ù½ð»áÖ×ÁöÑо¿Ëù£©
[2]. Turnier JL, Yee CM, Madison JA, Rizvi SM, Berthier CC, Wen F, Kahlenberg JM. Imaging mass cytometry reveals predominant innate immune signature and endothelial-immune cell interaction in juvenile myositis compared to lupus skin. Arthritis Rheumatol. 2022. Online ahead of print.£¨ÃÜЪ¸ù´óѧÄÚ¿Æѧϵ£©IF=13.3
[3]. Hill MC, Kadow ZA, Long H, Morikawa Y, Martin TJ, Birks EJ et al. Integrated multi-omic characterization of congenital heart disease. Nature. 2022. Online ahead of print.£¨ÐÝ˹¶Ù±´ÀÕҽѧԺ£©IF=64.8
[4]. Chang Q, Ornatsky OI, Siddiqui I, Loboda A, Baranov VI, Hedley DW. Imaging Mass Cytometry. Cytometry A. 2017;91(2):160-169.£¨Âê¸ñÀöÌع«Ö÷°©Ö¢ÖÐÐÄ£©
[5]. Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat Methods. 2014;11(4):417-422.£¨ËÕÀèÊÀ´óѧ·Ö×ÓÉúÃü¿ÆѧÑо¿Ëù£©IF=48.0